Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target remains the same with $135.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Buy rating due to a combination of factors influencing Gilead Sciences’ future prospects. A significant driver is the anticipated launch of lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP), which is expected to enhance Gilead’s market position due to its less frequent dosing advantage over current treatments. The potential FDA approval for LEN as a PrEP treatment by June 2025 is seen as a pivotal moment that could boost Gilead’s stock value.
Additionally, Gilead’s robust pipeline of next-generation HIV treatments, including long-acting oral and injectable options, is expected to yield several approvals by 2033. These developments, coupled with strategic market expansion efforts and innovative study designs to accelerate drug development, underpin Flynn’s positive outlook on Gilead’s growth trajectory.
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Eli Lilly & Co, and Gilead Sciences. According to TipRanks, Flynn has an average return of 2.7% and a 51.76% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $110.00 price target.